Making the case
Two Annual Meeting sessions engage in critical debate.
F023 – Great Debates in Medical Dermatology
1-3 p.m. | Friday, March 8
Room 1B
S061 – The 2024 Debates: Controversies in Dermatology
1-4 p.m. | Monday, March 11
Room 31B
Who doesn’t love a good debate? Two Annual Meeting sessions will lead robust discussions on current topics of importance to dermatologists. The two sessions include:
F023 – Great Debates in Medical Dermatology
This March 8 session will offer a look inside the challenges of caring for patients with medical dermatology disease, including neutrophilic dermatoses, SJS/TEN, and psoriasis as well as strategies for treating that unique patient population. Bridget Shields, MD, FAAD, assistant professor of dermatology at the University of Wisconsin School of Medicine, will lead the panel discussion that provides myriad points of view and case studies.
Treating patients with complex medical dermatology conditions takes knowledge, expertise, and even a cost-conscious mindset to manage such cases. Unfortunately, that combination is challenging within many dermatology practices, leaving many dermatologists hungry for guidance.
Scheduled speakers along with Dr. Shields include Dirk Michael Elston, MD, FAAD; Aaron Mangold, MD, FAAD; Robert Micheletti, MD, FAAD; Arash Mostaghimi, MD, MPH, FAAD; Misha Rosenbach, MD, FAAD; and Karolyn Wanat, MD, FAAD.
S061 – The 2024 Debates: Controversies in Dermatology
Evidence-based medicine is the conscientious and judicious use of the strongest current data in making decisions on how to care for patients. Advances in technology, development of new therapies, and acquisition of new data challenge the best practices and may stimulate controversy. This March 11 session features an interactive discussion regarding some of the emerging issues dermatologists are actively encountering in 2024.
Kenneth Y. Tsai, PhD, MD, FAAD, and Hensin Tsao, MD, PhD, FAAD, will co-direct the debate that critically evaluates key issues and challenges in deploying molecular testing for the determination of melanoma risk and outcomes, defines and recognizes the current opportunities and challenges with developing and using artificial intelligence (AI) applications in dermatology, and evaluates the key issues and challenges associated with melanoma (over)diagnosis and skin cancer screening.
Other presenters at the session include Emily Y. Chu, MD, PhD, FAAD; Pedram Gerami, MD, FAAD; Allan C. Halpern, MD, FAAD; David Polsky, MD, PhD, FAAD; Yevgeniy Semenov, MD, MS, FAAD; and Shannon Wongvibulsin, MD, PhD.
